Cargando…

A 2-yr Randomized Controlled Trial on Creatine Supplementation during Exercise for Postmenopausal Bone Health

PURPOSE: Our purpose was to examine the effects of 2 yr of creatine monohydrate supplementation and exercise on bone health in postmenopausal women. METHODS: Two hundred and thirty-seven postmenopausal women (mean age, 59 yr) were randomized to receive creatine (0.14 g·kg(−1)·d(−1)) or placebo durin...

Descripción completa

Detalles Bibliográficos
Autores principales: CHILIBECK, PHILIP D., CANDOW, DARREN G., GORDON, JULIANNE J., DUFF, WHITNEY R. D., MASON, RILEY, SHAW, KEELY, TAYLOR-GJEVRE, REGINA, NAIR, BINDU, ZELLO, GORDON A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487398/
https://www.ncbi.nlm.nih.gov/pubmed/37144634
http://dx.doi.org/10.1249/MSS.0000000000003202
Descripción
Sumario:PURPOSE: Our purpose was to examine the effects of 2 yr of creatine monohydrate supplementation and exercise on bone health in postmenopausal women. METHODS: Two hundred and thirty-seven postmenopausal women (mean age, 59 yr) were randomized to receive creatine (0.14 g·kg(−1)·d(−1)) or placebo during a resistance training (3 d·wk(−1)) and walking (6 d·wk(−1)) program for 2 yr. Our primary outcome was the femoral neck bone mineral density (BMD), with lumbar spine BMD and proximal femur geometric properties as the secondary outcomes. RESULTS: Compared with placebo, creatine supplementation had no effect on BMD of the femoral neck (creatine: 0.725 ± 0.110 to 0.712 ± 0.100 g·cm(−2); placebo: 0.721 ± 0.102 to 0.706 ± 0.097 g·cm(−2)), total hip (creatine: 0.879 ± 0.118 to 0.872 ± 0.114 g·cm(−2); placebo: 0.881 ± 0.111 to 0.873 ± 0.109 g·cm(−2)), or lumbar spine (creatine: 0.932 ± 0.133 to 0.925 ± 0.131 g·cm(−2); placebo: 0.923 ± 0.145 to 0.915 ± 0.143 g·cm(−2)). Creatine significantly maintained section modulus (1.35 ± 0.29 to 1.34 ± 0.26 vs 1.34 ± 0.25 to 1.28 ± 0.23 cm(3) (placebo), P = 0.0011), predictive of bone bending strength, and buckling ratio (10.8 ± 2.6 to 11.1 ± 2.2 vs 11.0 ± 2.6 to 11.6 ± 2.7 (placebo), P = 0.011), predictive of reduced cortical bending under compressive loads, at the narrow part of the femoral neck. Creatine reduced walking time over 80 m (48.6 ± 5.6 to 47.1 ± 5.4 vs 48.3 ± 4.5 to 48.2 ± 4.9 s (placebo), P = 0.0008) but had no effect on muscular strength (i.e., one-repetition maximum) during bench press (32.1 ± 12.7 to 42.6 ± 14.1 vs 30.6 ± 10.9 to 41.4 ± 14 kg (placebo)) and hack squat (57.6 ± 21.6 to 84.4 ± 28.1 vs 56.6 ± 24.0 to 82.7 ± 25.0 kg (placebo)). In the subanalysis of valid completers, creatine increased lean tissue mass compared with placebo (40.8 ± 5.7 to 43.1 ± 5.9 vs 40.4 ± 5.3 to 42.0 ± 5.2 kg (placebo), P = 0.046). CONCLUSIONS: Two years of creatine supplementation and exercise in postmenopausal women had no effect on BMD; yet, it improved some bone geometric properties at the proximal femur.